Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Salesforce Reports Q1 as Deal Rumors Die Down

No one’s buying.

Asa Mathat

Salesforce.com will report the results of its first fiscal quarter today just as chatter that it was the target of a takeover attempt have subsided.

Analysts are expecting Salesforce to report non-GAAP earnings of 14 cents on revenue of $1.5 billion, and to forecast earnings of 17 cents on $1.6 billion for the second quarter. But what Wall Street wants to hear is any commentary from CEO Marc Benioff on a potential sale. If he sticks to Salesforce’s standing policy of not commenting on “rumors and speculation,” then the conference call scheduled for later today will be an uneventful one.

Bloomberg reported on April 29 that Salesforce had hired unidentified bankers to field an offer expected from an unidentified suitor. Given its $45 billion market cap, attention quickly focused on three potential candidates: Microsoft, IBM and Oracle, with Google a potential but unlikely fourth and SAP also in the mix. Salesforce shares rose 10 percent on the report.

Even for the wealthiest of companies, acquiring Salesforce would be a huge undertaking. Since the initial report, the short list of potential buyers has ruled out a deal. Microsoft and Oracle have said they have no interest, while the CEO of SAP has said not once but twice that it wouldn’t be a buyer. (IBM has been suspiciously quiet on the subject.) In the three weeks since the rumors first hit, Salesforce shares have given back some, but notably not all, of their gains.

So what else will affect Salesforce’s results? Currencies. As a U.S.-based company that does a lot of business overseas — the government of Japan is one of its biggest customers — Salesforce takes a revenue hit when it gets paid in non-U.S. currencies because of the strong dollar. The company has already said it expects to absorb a hit on revenue of as much as $200 million in its fiscal 2016. Analyst Ross MacMillan of RBC Capital Markets said in a May 17 research note that the currency impact is expected to be most acute in the first and second quarters of the year. Additionally, currencies like the British pound, the euro and the Japanese yen have weakened further since Salesforce issued that guidance.

This article originally appeared on Recode.net.

See More:

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh